Eleanor Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eleanor Davies has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Guillaume Assié
Institut Cochin , INSERM U1016, CNRS UMR8104, F-75014 Paris
3 shared publicationsRobert Fraser
Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK
3 shared publicationsAngela Fisher
Medical Research Council Blood Pressure Group, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland G11 6NT
2 shared publications- Jaap Deinum
Department of Internal Medicine (N.P.R., J.D.), Radboud University Medical Center, Nijmegen, the Netherlands
2 shared publications - Laurence Amar
AP-HP, Hôpital Européen Georges Pompidou, Hypertension Unit and adrenal referral center; Centre de recherche des Cordeliers, Inserm, Université Paris-Cité, Sorbonne Université
2 shared publications Maria-Christina Zennaro
Inserm, PARCC, Université Paris Cité , F-75015 Paris
2 shared publications
Latest Publications
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii1-ii2
EndoCompass supplement: Preface, acknowledgements and declarations
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii1-ii2
Open AccessEndoCompass supplement: Preface, acknowledgements and declarations
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii170-ii176
EndoCompass project: artificial intelligence in endocrinology
Background: Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert analysis examined the current landscape of artificial intelligence (AI) applications in endocrinology, focusing on data sharing frameworks, fairness considerations, and training needs. Results: Research priorities encompass 3 domains: establishing compliant frameworks for clinical and omic data sharing in endocrinology; developing fair and unbiased AI systems that account for demographic and clinical diversity while preventing physician de-skilling; and creating comprehensive AI training programs for endocrinologists at all career stages. Special emphasis is placed on coordinating AI initiatives across medical specialties while maintaining endocrine-specific requirements. Conclusions: This component of the EndoCompass project provides an evidence-based roadmap for integrating AI into endocrine practice and research. The analysis demonstrates the need for balanced approaches that leverage AI capabilities while preserving clinical expertise. The findings support strategic investment in AI infrastructure, training, and fairness-aware system development.
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii170-ii176
Open AccessEndoCompass project: artificial intelligence in endocrinology
Background: Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert analysis examined the current landscape of artificial intelligence (AI) applications in endocrinology, focusing on data sharing frameworks, fairness considerations, and training needs. Results: Research priorities encompass 3 domains: establishing compliant frameworks for clinical and omic data sharing in endocrinology; developing fair and unbiased AI systems that account for demographic and clinical diversity while preventing physician de-skilling; and creating comprehensive AI training programs for endocrinologists at all career stages. Special emphasis is placed on coordinating AI initiatives across medical specialties while maintaining endocrine-specific requirements. Conclusions: This component of the EndoCompass project provides an evidence-based roadmap for integrating AI into endocrine practice and research. The analysis demonstrates the need for balanced approaches that leverage AI capabilities while preserving clinical expertise. The findings support strategic investment in AI infrastructure, training, and fairness-aware system development.
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii12-ii22
EndoCompass project: research roadmap for adrenal and cardiovascular endocrinology
Background: Endocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in adrenal endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: For adrenal disorders, research priorities span primary and secondary adrenal insufficiency, adrenal tumours, and endocrine hypertension. Key areas include development of biomarkers and replacement therapies, improved understanding of disease mechanisms, diagnostic procedure optimization, and establishment of pan-European registries. Special emphasis is placed on personalized treatment approaches. Conclusions: The adrenal component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into adrenal disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of adrenal disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii12-ii22
Open AccessEndoCompass project: research roadmap for adrenal and cardiovascular endocrinology
Background: Endocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in adrenal endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: For adrenal disorders, research priorities span primary and secondary adrenal insufficiency, adrenal tumours, and endocrine hypertension. Key areas include development of biomarkers and replacement therapies, improved understanding of disease mechanisms, diagnostic procedure optimization, and establishment of pan-European registries. Special emphasis is placed on personalized treatment approaches. Conclusions: The adrenal component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into adrenal disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of adrenal disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.
- Open Access
- 19 March 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (4) , 418-428
Identification of hypertension subtypes using microRNA profiles and machine learning
Objective: Hypertension is a major cardiovascular risk factor affecting about 1 in 3 adults. Although the majority of hypertension cases (∼90%) are classified as “primary hypertension” (PHT), endocrine hypertension (EHT) accounts for ∼10% of cases and is caused by underlying conditions such as primary aldosteronism (PA), Cushing's syndrome (CS), pheochromocytoma or paraganglioma (PPGL). EHT is often misdiagnosed as PHT leading to delays in treatment for the underlying condition, reduced quality of life and costly, often ineffective, antihypertensive treatment. MicroRNA (miRNA) circulating in the plasma is emerging as an attractive potential biomarker for various clinical conditions due to its ease of sampling, the accuracy of its measurement and the correlation of particular disease states with circulating levels of specific miRNAs. Methods: This study systematically presents the most discriminating circulating miRNA features responsible for classifying and distinguishing EHT and its subtypes (PA, PPGL, and CS) from PHT using 8 different supervised machine learning (ML) methods for the prediction. Results: The trained models successfully classified PPGL, CS, and EHT from PHT with area under the curve (AUC) of 0.9 and PA from PHT with AUC 0.8 from the test set. The most prominent circulating miRNA features for hypertension identification of different disease combinations were hsa-miR-15a-5p and hsa-miR-32-5p. Conclusions: This study confirms the potential of circulating miRNAs to serve as diagnostic biomarkers for EHT and the viability of ML as a tool for identifying the most informative miRNA species.
- 19 March 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (4) , 418-428
Open AccessIdentification of hypertension subtypes using microRNA profiles and machine learning
Objective: Hypertension is a major cardiovascular risk factor affecting about 1 in 3 adults. Although the majority of hypertension cases (∼90%) are classified as “primary hypertension” (PHT), endocrine hypertension (EHT) accounts for ∼10% of cases and is caused by underlying conditions such as primary aldosteronism (PA), Cushing's syndrome (CS), pheochromocytoma or paraganglioma (PPGL). EHT is often misdiagnosed as PHT leading to delays in treatment for the underlying condition, reduced quality of life and costly, often ineffective, antihypertensive treatment. MicroRNA (miRNA) circulating in the plasma is emerging as an attractive potential biomarker for various clinical conditions due to its ease of sampling, the accuracy of its measurement and the correlation of particular disease states with circulating levels of specific miRNAs. Methods: This study systematically presents the most discriminating circulating miRNA features responsible for classifying and distinguishing EHT and its subtypes (PA, PPGL, and CS) from PHT using 8 different supervised machine learning (ML) methods for the prediction. Results: The trained models successfully classified PPGL, CS, and EHT from PHT with area under the curve (AUC) of 0.9 and PA from PHT with AUC 0.8 from the test set. The most prominent circulating miRNA features for hypertension identification of different disease combinations were hsa-miR-15a-5p and hsa-miR-32-5p. Conclusions: This study confirms the potential of circulating miRNAs to serve as diagnostic biomarkers for EHT and the viability of ML as a tool for identifying the most informative miRNA species.
- Open Access
- 9 August 2017
- Published by Wiley in International Journal of Endocrinology
- Vol. 2017, 1-11
Regulation of Corticosteroidogenic Genes by MicroRNAs
The loss of normal regulation of corticosteroid secretion is important in the development of cardiovascular disease. We previously showed that microRNAs regulate the terminal stages of corticosteroid biosynthesis. Here, we assess microRNA regulation across the whole corticosteroid pathway. Knockdown of microRNA using Dicer1 siRNA in H295R adrenocortical cells increased levels of CYP11A1, CYP21A1, and CYP17A1 mRNA and the secretion of cortisol, corticosterone, 11-deoxycorticosterone, 18-hydroxycorticosterone, and aldosterone. Bioinformatic analysis of genes involved in corticosteroid biosynthesis or metabolism identified many putative microRNA-binding sites, and some were selected for further study. Manipulation of individual microRNA levels demonstrated a direct effect of miR-125a-5p and miR-125b-5p on CYP11B2 and of miR-320a-3p levels on CYP11A1 and CYP17A1 mRNA. Finally, comparison of microRNA expression profiles from human aldosterone-producing adenoma and normal adrenal tissue showed levels of various microRNAs, including miR-125a-5p to be significantly different. This study demonstrates that corticosteroidogenesis is regulated at multiple points by several microRNAs and that certain of these microRNAs are differentially expressed in tumorous adrenal tissue, which may contribute to dysregulation of corticosteroid secretion. These findings provide new insights into the regulation of corticosteroid production and have implications for understanding the pathology of disease states where abnormal hormone secretion is a feature.
- 9 August 2017
- Published by Wiley in International Journal of Endocrinology
- Vol. 2017, 1-11
Open AccessRegulation of Corticosteroidogenic Genes by MicroRNAs
The loss of normal regulation of corticosteroid secretion is important in the development of cardiovascular disease. We previously showed that microRNAs regulate the terminal stages of corticosteroid biosynthesis. Here, we assess microRNA regulation across the whole corticosteroid pathway. Knockdown of microRNA using Dicer1 siRNA in H295R adrenocortical cells increased levels of CYP11A1, CYP21A1, and CYP17A1 mRNA and the secretion of cortisol, corticosterone, 11-deoxycorticosterone, 18-hydroxycorticosterone, and aldosterone. Bioinformatic analysis of genes involved in corticosteroid biosynthesis or metabolism identified many putative microRNA-binding sites, and some were selected for further study. Manipulation of individual microRNA levels demonstrated a direct effect of miR-125a-5p and miR-125b-5p on CYP11B2 and of miR-320a-3p levels on CYP11A1 and CYP17A1 mRNA. Finally, comparison of microRNA expression profiles from human aldosterone-producing adenoma and normal adrenal tissue showed levels of various microRNAs, including miR-125a-5p to be significantly different. This study demonstrates that corticosteroidogenesis is regulated at multiple points by several microRNAs and that certain of these microRNAs are differentially expressed in tumorous adrenal tissue, which may contribute to dysregulation of corticosteroid secretion. These findings provide new insights into the regulation of corticosteroid production and have implications for understanding the pathology of disease states where abnormal hormone secretion is a feature.
- Open Access
- 1 September 2001
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (9) , 4326-4329
Effects of 18-Hydroxylated Steroids on Corticosteroid Production by Human Aldosterone Synthase and 11β-Hydroxylase
In glucocorticoid-suppressible hyperaldosteronism, 11β- hydroxylase activity is impaired. A chimeric enzyme formed from the control elements of 11β-hydroxylase and the structural elements of aldosterone synthase is expressed ectopically in the zona fasciculata, thus exposing cortisol to aldosterone synthase. Increased quantities of 18-hydroxycortisol and 18-oxocortisol are synthesized, which, it has been suggested, might have a local inhibitory effect on the normal 11β-hydroxylase. The effects of these compounds and also of 18-hydroxydeoxycorticosterone were tested in cells stably transfected with CYP11B1 and CYP11B2, the genes encoding 11β-hydroxylase and aldosterone synthase, respectively. Neither 18-hydroxycortisol nor 18-oxocortisol affected the efficiency of use of 11-deoxycorticosterone or 11-deoxycortisol as substrates by the enzymes. 18-Hydroxydeoxycorticosterone significantly reduced the conversion rate of 11-deoxycorticosterone to corticosterone and that of 11-deoxycortisol to cortisol by both enzymes, but the production rate of 18- hydroxycorticosterone and aldosterone by aldosterone synthase increased. Aldosterone synthase was able to convert 18-hydroxydeoxycorticosterone to 18-hydroxycorticosterone and aldosterone, although its affinity for this substrate was lower (4.76μ mol/liter) than that for 11-deoxycorticosterone (0.11 μmol/liter). 11β-Hydroxylase was unable to convert 18- hydroxydeoxycorticosterone to 18-hydroxycorticosterone. 18-Hydroxycortisol and 18-oxocortisol are not, therefore, the cause of lower 11β-hydroxylase activity in glucocorticoid- suppressible hyperaldosteronism. 18-Hydroxydeoxycorticosterone can be converted to aldosterone, but its local concentration in man and its Km suggest that it is unlikely to be important.
- 1 September 2001
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (9) , 4326-4329
Open AccessEffects of 18-Hydroxylated Steroids on Corticosteroid Production by Human Aldosterone Synthase and 11β-Hydroxylase
In glucocorticoid-suppressible hyperaldosteronism, 11β- hydroxylase activity is impaired. A chimeric enzyme formed from the control elements of 11β-hydroxylase and the structural elements of aldosterone synthase is expressed ectopically in the zona fasciculata, thus exposing cortisol to aldosterone synthase. Increased quantities of 18-hydroxycortisol and 18-oxocortisol are synthesized, which, it has been suggested, might have a local inhibitory effect on the normal 11β-hydroxylase. The effects of these compounds and also of 18-hydroxydeoxycorticosterone were tested in cells stably transfected with CYP11B1 and CYP11B2, the genes encoding 11β-hydroxylase and aldosterone synthase, respectively. Neither 18-hydroxycortisol nor 18-oxocortisol affected the efficiency of use of 11-deoxycorticosterone or 11-deoxycortisol as substrates by the enzymes. 18-Hydroxydeoxycorticosterone significantly reduced the conversion rate of 11-deoxycorticosterone to corticosterone and that of 11-deoxycortisol to cortisol by both enzymes, but the production rate of 18- hydroxycorticosterone and aldosterone by aldosterone synthase increased. Aldosterone synthase was able to convert 18-hydroxydeoxycorticosterone to 18-hydroxycorticosterone and aldosterone, although its affinity for this substrate was lower (4.76μ mol/liter) than that for 11-deoxycorticosterone (0.11 μmol/liter). 11β-Hydroxylase was unable to convert 18- hydroxydeoxycorticosterone to 18-hydroxycorticosterone. 18-Hydroxycortisol and 18-oxocortisol are not, therefore, the cause of lower 11β-hydroxylase activity in glucocorticoid- suppressible hyperaldosteronism. 18-Hydroxydeoxycorticosterone can be converted to aldosterone, but its local concentration in man and its Km suggest that it is unlikely to be important.
- Open Access
- 1 March 2000
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 85 (3) , 1261-1266
Amino Acid Residue 147 of Human Aldosterone Synthase and 11β-Hydroxylase Plays a Key Role in 11β-Hydroxylation*
A number of amino acids differ between aldosterone synthase and 11β-hydroxylase. To assess their importance in determining the different functional specificities, we substituted aldosterone synthase-specific (aspartate D147, isoleucine I248, glutamine Q43, and threonine T493) with 11β-hydroxylase-specific amino acids (glutamate E147, threonine T248, arginine R43, and methionine M493), respectively. I248T, Q43R, and T493M had no effect on steroid production compared to wild-type aldosterone synthase. However, CYP11B2-D147E caused a significant increase in corticosterone production and a smaller increase in aldosterone production from 11-deoxycorticosterone (DOC). This appeared to be predominantly due to an increase in the 11β-hydroxylation of DOC to corticosterone mediated by a decrease in Km, which was 1.4 μmol/L for the mutant compared with 5μ mol/L for the wild-type enzyme. CYP11B2-D147E had no effect on the conversion of 11-deoxycortisol to cortisol. The reverse construct (CYP11B1-E147D), substituting the 11β-hydroxylase residue with the aldosterone synthase equivalent, decreased the conversion of DOC to corticosterone, which was mediated by an increase in Km that was 7.5 μmol/L for the mutant compared with 2.5 μmol/L for the wild-type enzyme. Again, the conversion of 11-deoxycortisol to cortisol was unimpaired. Thus, amino acid 147 is involved in the transformation of the 17-deoxysubstrate, but not the 17α-hydroxysubstrate. The results demonstrate that a conservative change in amino acid, even at some linear distance from known active centers, can significantly affect enzyme substrate affinity and subsequent steroid hormone production.
- 1 March 2000
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 85 (3) , 1261-1266
Open AccessAmino Acid Residue 147 of Human Aldosterone Synthase and 11β-Hydroxylase Plays a Key Role in 11β-Hydroxylation*
A number of amino acids differ between aldosterone synthase and 11β-hydroxylase. To assess their importance in determining the different functional specificities, we substituted aldosterone synthase-specific (aspartate D147, isoleucine I248, glutamine Q43, and threonine T493) with 11β-hydroxylase-specific amino acids (glutamate E147, threonine T248, arginine R43, and methionine M493), respectively. I248T, Q43R, and T493M had no effect on steroid production compared to wild-type aldosterone synthase. However, CYP11B2-D147E caused a significant increase in corticosterone production and a smaller increase in aldosterone production from 11-deoxycorticosterone (DOC). This appeared to be predominantly due to an increase in the 11β-hydroxylation of DOC to corticosterone mediated by a decrease in Km, which was 1.4 μmol/L for the mutant compared with 5μ mol/L for the wild-type enzyme. CYP11B2-D147E had no effect on the conversion of 11-deoxycortisol to cortisol. The reverse construct (CYP11B1-E147D), substituting the 11β-hydroxylase residue with the aldosterone synthase equivalent, decreased the conversion of DOC to corticosterone, which was mediated by an increase in Km that was 7.5 μmol/L for the mutant compared with 2.5 μmol/L for the wild-type enzyme. Again, the conversion of 11-deoxycortisol to cortisol was unimpaired. Thus, amino acid 147 is involved in the transformation of the 17-deoxysubstrate, but not the 17α-hydroxysubstrate. The results demonstrate that a conservative change in amino acid, even at some linear distance from known active centers, can significantly affect enzyme substrate affinity and subsequent steroid hormone production.